|1.||Yamaguchi, Tokio: 3 articles (01/2004 - 01/2002)|
|2.||Kawasaki-Yatsugi, Sachiko: 2 articles (01/2004 - 01/2002)|
|3.||Miyata, Keiji: 2 articles (04/2003 - 01/2003)|
|4.||Suzuki, Masanori: 2 articles (04/2003 - 01/2003)|
|5.||Sasamata, Masao: 2 articles (04/2003 - 01/2003)|
|6.||Takahashi, Masayasu: 2 articles (03/2003 - 01/2002)|
|7.||Takahashi, M: 2 articles (01/2003 - 01/2000)|
|8.||Ohtani, Toshiyuki: 1 article (04/2013)|
|9.||Aihara, Masanori: 1 article (04/2013)|
|10.||Watanabe, Takashi: 1 article (04/2013)|
01/01/2002 - "The evidence for the neuroprotective efficacy of YM872 suggests its therapeutic potential in the treatment of acute stroke in humans."
01/04/2000 - "YM872 shows promise as an effective treatment for patients suffering from acute stroke."
02/01/1998 - "This evidence for the neuroprotective efficacy of YM872 suggests its therapeutic potential in the treatment of acute stroke in humans."
01/01/2002 - "Phase II studies of YM872 in acute ischaemic stroke are ongoing."
01/03/2003 - "Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model."
01/01/2002 - "In addition, YM872 significantly improved neurological deficit measured at 1 week after ischemia. "
10/01/1998 - "These results indicate that YM872 is a neuroprotective compound that ameliorates the deterioration of the hemodynamic penumbra after focal ischemia."
01/01/2002 - "In cats with MCAO YM872, by i.v. infusion, dose-dependently reduced infarct volume at 6 h after ischemia. "
01/01/2002 - "In rats with occluded middle cerebral artery (MCAO) YM872, by i.v. infusion, significantly reduced infarct volume measured at 24 h and 1 week after ischemia. "
11/01/1998 - "YM872 significantly reduced infarct volume in both 4- and 24-hr treatment groups measured 24 hr after ischemia. "
|3.||Brain Ischemia (Cerebral Ischemia)
02/01/1998 - "YM872, a novel selective alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats."
05/18/1998 - "The present study indicates that the neuroprotective effect of YM872 is enhanced by extending the duration of treatment, and demonstrates the benefit of the prolonged treatment with AMPA antagonists following focal cerebral ischemia. "
05/18/1998 - "The neuroprotective effect of YM872 ([2.3-dioxo-7-(1H-imidazol-1-yl) 6-nitro-1,2,3,4-tetrahydro-1-quinoxalinyl]acetic acid monohydrate), a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonist with improved water solubility, was examined in a rat focal cerebral ischemia model. "
02/01/1998 - "YM872 ([2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3, 4-tetrahydro-1-quinoxalinyl]-acetic acid monohydrate), a selective, potent and highly water-soluble competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist, was investigated for its neuroprotective effect against focal cerebral ischemia in halothane-anesthetized cats. "
|4.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
11/01/1998 - "Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats."
01/04/2000 - "Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model."
05/18/1998 - "A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats."
|5.||Brain Edema (Cerebral Edema)
01/01/2003 - "Our results indicate that the post-traumatic administration of YM872 may be neuroprotective by reducing BBB breakdown and regional cerebral edema."
01/01/2003 - "The administration of YM872 resulted in a significant reduction in regional cerebral edema in the injured parietal cortex and a markedly reduced area of IgG immunoreactivy in the injured cortex. "
03/01/2003 - "These results indicate that the posttraumatic administration of YM872 may be neuroprotective by ameliorating cortical tissue loss and regional cerebral edema, and suggest the importance of AMPA receptors in traumatic brain damage involving secondary injury processes."
03/01/2003 - "The glutamate AMPA receptor antagonist, YM872, attenuates cortical tissue loss, regional cerebral edema, and neurological motor deficits after experimental brain injury in rats."
01/01/2003 - "The glutamate AMPA receptor antagonist, YM872, attenuates regional cerebral edema and IgG immunoreactivity following experimental brain injury in rats."
|1.||AMPA Receptors (AMPA Receptor)
|2.||Acetic Acid (Vinegar)
|3.||Immunoglobulin G (IgG)
|4.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|6.||Glutamic Acid (Glutamate)
|3.||Heterologous Transplantation (Xenotransplantation)